Health Care & Life Sciences » Biotechnology | Microbix Biosystems Inc.

Microbix Biosystems Inc. | Income Statement

Fiscal year is October-September. All values CAD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
7,574.60
8,396.80
8,873.90
9,517.10
10,185.80
12,510.60
Cost of Goods Sold (COGS) incl. D&A
3,893.60
4,010.10
3,160.00
4,660.50
5,575.10
7,304.20
Gross Income
3,681.00
4,386.70
5,713.90
4,856.60
4,610.70
5,206.30
SG&A Expense
2,975.30
3,070.00
4,622.50
4,017.60
5,185.70
5,097.30
EBIT
705.70
1,316.70
1,091.40
839.00
574.90
109.10
Unusual Expense
-
-
-
-
2,730.60
7,878.80
Non Operating Income/Expense
131.40
-
-
-
-
-
Interest Expense
678.10
850.90
745.20
691.30
924.60
852
Pretax Income
168.20
475.60
349.00
148.40
4,230.10
8,621.60
Income Tax
166.80
306.60
265.00
600.00
450.00
-
Consolidated Net Income
1.40
169.00
614.00
748.40
3,780.10
8,621.60
Net Income
1.40
169.00
614.00
748.40
3,780.10
8,621.60
Net Income After Extraordinaries
1.40
169.00
614.00
748.40
3,780.10
8,621.60
Net Income Available to Common
1.40
169.00
614.00
748.40
3,780.10
8,621.60
EPS (Basic)
-
0.00
0.01
0.01
0.04
0.09
Basic Shares Outstanding
66,600.00
68,977.20
80,868.90
84,656.50
84,704.30
96,198.80
EPS (Diluted)
0.00
0.00
0.01
0.01
0.04
0.09
Diluted Shares Outstanding
66,600.00
72,231.90
82,147.40
84,705.80
84,704.30
96,198.80
EBITDA
1,124.90
1,720.00
1,509.80
1,252.70
64.80
799.10
Non-Operating Interest Income
9.20
9.80
2.80
0.60
0.00
0.20

About Microbix Biosystems

View Profile
Address
265 Watline Avenue
Mississauga Ontario L4Z 1P3
Canada
Employees -
Website http://www.microbix.com
Updated 07/08/2019
Microbix Biosystems, Inc. engages in the manufacture of viral and bacterial antigens and reagents for the global diagnostics industry. Its biological solutions include products for human health applications in the vaccine, therapeutic and diagnostic markets, and a product for the worldwide animal reproduction market. Its pipeline of technologies and products include LumiSort, semen sexing technology for the livestock industries; and Kinlytic, a thrombolytic drug for life-threatening blood clots.